

**2020
VIRTUAL
MEETING**



**2020
VIRTUAL
MEETING**

**The NEW HORIZONS GIST Patient Advocacy Roundtable:
Improving access to treatment and quality of care through global exchange.**

**Since 2003: The best opportunity of the year to learn from
leading GIST-Experts and GIST-Patient Advocates!**

Every year, the global GIST community brings together leading GIST experts and GIST patient advocates to learn, share and discuss.

Despite our best efforts, it has become clear that this year's New Horizons GIST 2020 Patient Advocacy Meeting on 10th – 12th of September 2020 will be a Virtual Meeting.

We are delighted that we will have a very interesting programme over 3 half days with a great group of leading speakers providing their knowledge about diagnosis, treatment and care of GIST and the possibility to discuss the challenges and needs of the Global GIST Community.

The meeting takes place between 10th and 12th of September starting each day at 14:00 CEST/CEDST. Please check your individual time zone!

Global Conference-Timing (for some selected locations):

08:00 New York / Toronto EST/EDST	09:00 Santiago de Chile
13:00 London	14:00 Berlin CEST/CEDST
17:30 Mumbai	21:00 Tokyo

Looking forward to meeting you all online for a great New Horizons GIST 2020 Patient Advocacy Meeting!

The NEW HORIZONS GIST Steering Committee

<i>Piga Fernandez (Alianza GIST)</i>	<i>David Josephy (Life Raft Group Canada)</i>
<i>Sara Rothschild (Life Raft Group USA)</i>	<i>Ginger Sawyer (GSI International USA)</i>
<i>Norman Scherzer (Life Raft Group USA)</i>	<i>Martin Wettstein (GIST-Group Switzerland)</i>
<i>Markus Wartenberg (German Sarcoma Foundation/SPAEN)</i>	



The NEW HORIZONS GIST Patient Advocacy Roundtable:
Improving access to treatment and quality of care through global exchange.

THURSDAY September 10, 2020

**08:00 EDST/
14:00 CEDST OFFICIAL START OF THE MEETING**

**08:00 – 08:30
14:00 – 14:30**
(30 min)
COVID-19: Conferences in the age of a global pandemic...
Opening, Welcome, Organizational & Technical Issues, Thanks to the Sponsors, etc.
Markus Wartenberg – on behalf of the NH GIST Steering Committee
Short Welcome Notes from our Sponsor-Partners:
Geoff Cook (Novartis), Nicholas Taylor (Blueprint), Stephanie Bryant (Deciphera)

**08:30 – 09:30
14:30 – 15:30**
(60 min)
GIST Episode 1: Introduction – Overview
Moderator / Patient-Chair: Martin Wettstein (CH)
Speaker: Hans Gelderblom (NL)

- History of GIST - Numbers - Facts – Overview
- Diagnosis/Examination - Imaging – Lab Values
- Main Treatment Options (brief treatment algorithms)
- General important tips/core recommendations for patients

Each Episode – will have two parts:
Part A: Necessary (basic) knowledge for GIST-patients (recorded for the public, for GIST-patients globally) up to 30 min.
Part B: Deeper info for patient advocates, discussion, core messages for the report (recorded just for our community) up to 30 min.

09:30/15:30 BREAK FROM ON SCREEN (30 min.)

**10:00 – 11:00
16:00 – 17:00**
(60 min)
GIST Episode 2: Biology – Genetics – Pathology
Moderator / Patient-Chair / Speaker: David Josephy (CDN)

- Biology/Genetics/Targets of/in GIST
- Role of the pathologists in GIST
- Mutational Analysis / Genotyping

11:00/17:00 BREAK FROM ON SCREEN (30 min.)

**11:30 – 12:30
17:30 – 18:30**
(60 min)
GIST Episode 3: Localized, operable primary tumor
Moderator / Patient-Chair: Markus Wartenberg (DE)
Speaker: Peter Reichardt (DE)

- Surgery of primary tumors at multiple sites
- Risk stratification for adjuvant therapy and follow-up
- Neoadjuvant and adjuvant Imatinib (Glivec/Gleevec) therapy (incl. 10 years data for 36 months adj. treatment)

12:30 / 18:30 End of Day 1



The NEW HORIZONS GIST Patient Advocacy Roundtable:
Improving access to treatment and quality of care through global exchange.

FRIDAY September 11, 2020

<p>08:00 – 09:00 14:00 – 15:00 (60 min)</p>	<p>GIST Episode 4: Metastatic (advanced) disease <i>Moderator / Patient-Chair: David Josephy (CDN)</i> <i>Speaker: Albiruni Razak (CDN)</i></p> <ul style="list-style-type: none"> • First-line treatment with Imatinib (Glivec/Gleevec) • Main side effects and drug interactions • Response to therapy and monitoring • What to do with initial/early Imatinib intolerance? • The role of surgery in metastatic disease • Mutation D842V: Treatment with Avapritinib (Ayvakit™) (= brief overview) (Reference to more information in Episode 6)
---	--

09:00/15:00 BREAK FROM ON SCREEN (30 min.)

<p>09:30 – 10:30 15:30 – 16:30 (60 min)</p>	<p>GIST Episode 5: Progression of metastatic disease under drug treatment <i>Moderator / Patient-Chair: Laura Occhiuzzi (USA)</i> <i>Speaker: Breelyn Wilky (USA)</i></p> <ul style="list-style-type: none"> • Reasons for resistance e.g. secondary mutations • Verification of tumor progression and overview current available treatments • Treatments with Sunitinib (Sutent™) and Regorafenib (Stivarga™) • Main side effects and drug interactions • Locally ablative procedures to remove single progressive lesions (surgery, chemo-embolization, RFA/microwave, IRE, SIRT...)
---	--

10:30/16:30 BREAK FROM ON SCREEN (30 min.)

<p>11:00 – 12:00 17:00 – 18:00 (60 min)</p>	<p>GIST Episode 6: Introducing new treatment options in GIST <i>Moderator / Patient-Chair: Sara Rothschild (USA)</i> <i>Speaker: Jon Trent (USA)</i></p> <p>Targets – Treatments – Clinical Trial Data – Side Effects – Study-Outlook</p> <ul style="list-style-type: none"> • NEW against Mutation D842V: Introducing BLU-285/Avapritinib/Ayvakit™ • NEW 4th Line treatment: Introducing DCC-2618/Ripretinib/Qinlock™
---	--

12:00 / 18:00 End of Day 2



The NEW HORIZONS GIST Patient Advocacy Roundtable:
Improving access to treatment and quality of care through global exchange.

SATURDAY September 12, 2020

<p>08:00 – 09:00 14:00 – 15:00 (60 min)</p>	<p>GIST Episode 7: Challenges in approaching a non-KIT/PDGFR mutated GIST <i>Moderator / Patient-Chair: Jayne Bressington (UK)</i> <i>Speaker/s: Ramesh Bulusu (UK) + Dr. Casey (UK)</i></p> <ul style="list-style-type: none"> • Understanding the term “wild-type” • Understanding the heterogeneity of subtypes in GIST today >>> sub-types, biology, targets, etc. • Practical experiences: How to treat the various subtypes?
---	---

09:00/15:00 BREAK FROM ON SCREEN (30 min.)

<p>09:30 – 10:30 15:30 – 16:30 (60 min)</p>	<p>GIST Episode 8: Following the research journey in GIST <i>Moderator / Patient-Chair: Pete Knox (USA)</i> <i>Speaker: Robin Jones (UK)</i></p> <ul style="list-style-type: none"> • Nilotinib, Everolimus, Dasatinib, Ponatinib and others: Therapies that have never been approved for GIST - but could be options (e.g. off label use) • What role does Larotrectinib (Vitrakvi) play in GIST treatment? • Current & upcoming agents / clinical trials in GIST
---	--

10:30/16:30 BREAK FROM ON SCREEN (30 min.)

<p>11:00 – 12:00 17:00 – 18:00 (60 min)</p>	<p>GIST Episode 9: Quality of diagnosis, treatment & care <i>Moderator / Patient-Chair: Ginger Sawyer (USA) / Piga Fernandez (CHI)</i> <i>Speaker: Gina D'Amato (USA)</i></p> <ul style="list-style-type: none"> • Adherence: The importance of professional therapy and side effect management: Getting the best out of the treatments. The Patient Perspective AND the Expert-Perspective... • Discussion: Living with the disease Influencing Factors such as Nutrition, Complementary Therapies, Coping etc. Challenges for patients, carers (incl. long term survivors)
---	---

<p>18:00</p>	<p>Wrap Up & Farewell - OFFICIAL END OF THE CONFERENCE and END OF TRANSMISSION</p>
--------------	---

12:15 / 18:15 End of the New Horizons GIST 2020 meeting